Clinical studies confirmed that KRASG12C inhibitors in conjunction with ICIs elicit substantial antitumor activity in NSCLC patients, achieving an ORR of 63% in individuals with a programmed cell death 1 ligand 1 (PD-L1) tumor proportion score (TPS) of greater than, or equal to, 50%. Here, CD274 is linked to neoplasm.